Huge technological advancements in diabetes management have been achieved during the past decade, such as the development of the modern flash/continuous glucose monitoring (FGM/CGM), insulin pumps, and automated insulin delivery (AID) systems, creating a paradigm shift in Type 1 Diabetes Mellitus (T1DM) standards of care (9), although the impact of these devices in individuals with CFRD is less clear (10). This evidence concerns the gene INS and diabetes mellitus.